SNPHF (Santen Pharmaceutical Co) Tariff Resilience Score: 6/10 (As of Jul. 02, 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
81 GF Score
Price $13.05
GF Value $10.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Tariff Resilience Score?

Santen Pharmaceutical Co SNPHF +4.40% 81 Tariff Resilience Score is 6 as of Jul. 02, 2026. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.23 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 91.17% on this metric.

Santen Pharmaceutical Co has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Santen Pharmaceutical Co has Santen Pharmaceutical Co Ltd operates in the pharmaceutical industry with global sales. It faces moderate tariff risks on raw materials and finished products. The company has some pricing power and can leverage its global manufacturing network to mitigate tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Santen Pharmaceutical Co might have Average Resilient.

Santen Pharmaceutical Co  (OTCPK:SNPHF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Santen Pharmaceutical Co Tariff Resilience Score Related Terms

SNPHF vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santen Pharmaceutical Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Tariff Resilience Score falls into.


SNPHF
81GF Score
Santen Pharmaceutical Co Ltd SNPHF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Santen Pharmaceutical Co (SNPHF) has a Tariff Resilience Score of 6 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Santen Pharmaceutical Co ranks #91 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Santen Pharmaceutical Co's Tariff Resilience Score too high?
Santen Pharmaceutical Co's current Tariff Resilience Score is 6. Based on the distribution chart, Santen Pharmaceutical Co ranks #91 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #91 out of 1030 companies for Tariff Resilience Score. This places Santen Pharmaceutical Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Santen Pharmaceutical Co's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.23, compared to a current price of $13.05 — trading 27.6% above its estimated fair value. The current Tariff Resilience Score is 6. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Tariff Resilience Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.6% above its estimated GF Value™ of $10.23. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Tariff Resilience Score: 6
  • GF Value™: $10.23 vs. price of $13.05 (27.6% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
81GF Score

Get the complete analysis for SNPHF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.23
GF Value